Pfizer’s Anticipated Quarterly Earnings
Analysts on Wall Street are predicting that Pfizer (PFE) will report quarterly earnings of $0.58 per share in its upcoming earnings announcement, marking a 3.3% decrease compared to the same period last year. Revenue is expected to hit $13.78 billion, reflecting a 3.7% increase from the previous year. Over the past month, the consensus EPS estimate has been adjusted downward by 0.2%, indicating a collective reevaluation by analysts covering the stock.
The Importance of Earnings Estimate Revisions
Prior to a company’s earnings release, it is essential to take into account any changes made to earnings forecasts. These revisions serve as a critical gauge for anticipating how investors may react to the stock. Numerous studies have shown a strong link between earnings estimate revisions and short-term stock price movements. While investors often rely on consensus earnings and revenue projections as benchmarks for assessing quarterly performance, a close examination of analysts’ estimates for key metrics can provide a more thorough understanding.
Key Revenue Estimates for Pfizer
With this in mind, let’s explore the average estimates for various Pfizer metrics that Wall Street analysts frequently track. Analysts expect ‘Revenues- Oncology- Ibrance- Worldwide’ to reach $1.05 billion, indicating a year-over-year decline of 6.9%. For ‘Revenues- Specialty Care- Xeljanz- Worldwide’, the estimate is set at $219.35 million, reflecting a significant drop of 27.6% compared to the same quarter last year.
The combined prediction for ‘Revenues- Oncology- Xtandi alliance revenues- Worldwide’ stands at approximately $528.19 million, representing a 6.7% increase year over year. Meanwhile, analysts have projected revenues for ‘Specialty Care- Inflectra- Worldwide’ to be around $101.04 million, which suggests a year-over-year growth of 4.2%.
Further, analysts anticipate ‘Revenues- Oncology- Ibrance- United States’ to be $702.67 million, indicating a 5.2% decrease from the previous year. The consensus forecast for ‘Revenues- Specialty Care- Xeljanz- Total International’ is $103.19 million, down 15.4% from the same quarter last year.
According to analyst assessments, ‘Revenues- Oncology- Ibrance- Total International’ is projected to be approximately $349.94 million, reflecting a year-over-year decline of 10.3%. The estimate for ‘Revenues- Specialty Care- Xeljanz- United States’ is expected to reach $116.16 million, which indicates a staggering year-over-year drop of 35.8%.
Analysts also estimate that ‘Revenues- Oncology- Inlyta- Total International’ will amount to $89.23 million, a decrease of 11.7% compared to the prior-year quarter. For the ‘Revenues- Oncology- Inlyta- United States’, projections suggest a figure of $116.62 million, showing a decline of 22.8% year over year.
Looking at primary care, analysts predict that ‘Revenue- Primary Care- Prevnar family- United States’ will be around $826.39 million, reflecting a slight decrease of 0.7%. Conversely, ‘Revenue- Primary Care- Prevnar family- Total International’ is expected to reach $536.11 million, indicating a 1.7% increase from the previous year.
Pfizer’s Stock Performance
In the past month, Pfizer’s shares have declined by 6%, contrasting with the Zacks S&P 500 composite, which has increased by 2.7%. Currently holding a Zacks Rank of #3 (Hold), PFE is anticipated to closely mirror the overall market trends in the near future.
No coins selected
